Member Info for Chrisatrdg

I think what has happened is that the SP increased gradually on the anticipation of some positive news coming this summer from one of the conferences re: a C-Diff deal driven primarily stateside but with no news people are taking profit or moving on.

Back to basics - If the current AIM & NASDAQ SP can hold it now makes for a good platform for the next stage i.e £2.50 ASK.Hopefully I am not dreaming but with currently sound science this share must now start to progress if it is going to at all.

Final close on NASDAQ was $13.78 (Friday High) which at current exchange rates is £2.10 hopefully this will further increase next week & pull AIM up further next week. Recent publication per AM below seems to have created further interest.In addition 7,983 was the total numbers & included as last transaction of 1,000 at $13.7674. Momentum is building & it is still the 'Summer' - roll on £2.50 (Ask).

At last someone biting at £2.10 today hopefully this will help build some momentum but still a way to go before the SP is anyway near where it should be.

Final close $13.62 which at todays exchange rate is £2.08 & again is ahead of AIM which is slowly catching up also note there were a large number of transaction today 51,197.Clearly an increase in interest in Summit state side fuelling the notion that SRPT may have their own interest in SMMT following recent funds raise possible creating a SRPT war chest.

I agree with Free-Money & still feel that RDZ is the ace in the pack to underscore the SP.Glyn was again talking about a RDZ deal this summer & non dilutive so hold onto your seats. My reading of the situation is not that its a matter of the RDZ (C-Diff product) being successful but when it will go to market.When asked by when it was possible to have the RDZ tablets on the shelves Glyn answered 2020 (to be corrected if need be). All looking positive.

See you there Free-Money looking forward to C-Diff update.

As things currently stand NASDAQ is at £1.94 up 6.49% using current exchange rate putting AIM somewhat behind.Clearly greater interest currently in USA hopefully AIM will catch up soon.Article per link below makes for a great platform for some future C-Diff investor (hopefully soon - 'This summer'?).

http://www.pharmaceutical-journal.com/news-and-analysis/news/powerful-antibiotic-against-c-difficile-to-be-tested-in-phase-iii-clinical-trial/20203164.article Above from Summit twitter feed. AGM thoughts/questions RDZ With the cost of 2 x 700 trials at least $100m we will need a 'friend' with deep pockets. Given where we are, and assuming no 'grant' money comes our way, one of the 'many' term sheets we have/had on the table will need to pony up the $100m as I can't see us having 'spare' funds beyond paying for our split of future ETZ trials. So what percentage should we 'give' away in return for the $100m funding? (Wellcome I assume would also be diluted from current 20/25% they have rights on. ETZ Re future funding needs on ETZ . Are they willing/able to attempt to fund both drugs as previously said wouldn't. If the F3 data looks weak, but F6 a lot better, given the 30:10 patent split, does that mean further trials before phase 3.

https://www.summitplc.com/investors/presentations/

Posted this evening on twitter & posted on Summit Presentations Page:Slingshot Insights Management Call - 28 June 2017 Listen In http://www.summitplc.com/investors/presentations/ Slingshot members are talking to management! The topic is:Interviewing the CEO of Summit Therapeutics to discuss the company's leading clinical stage DMD and C Diff programs https://slingshotinsights.com/projects/501

RARECast - Glyn Edwards see Summit twitter a/c Summit Pursues A Different Approach to Treating Duchenne https://soundcloud.com/rarecast/summit-pursues-a-different-approach-to-treating-duchenne

Out today: JMP Life Sciences Conference 21 June 2017 Developing Clinical Stage Programs to Treat DMD and CDI Company Presentation June 2017 http://g923gvc6go14zuzz1vaotb19.wpengine.netdna-cdn.com/wp-content/uploads/2015/06/201706_Company-Presentation-June-JMP-001.pdf

Good to see some positive trading before the normal 12.00 RNS time.Patiently waiting for the C-Diff deal RNS expected this summer or has that been moved as well.If you get my drift.

Good to see 1st Qtr's results out Wednesday this week - might help support current SP.

Hi Free-Money - I am going to AGM this year & went last year so see you there.I am also fully invested & confident although I did some de-risking last October now owning 40k shares (54% up).I started investing in Feb. 2010 & it has had many ups & downs but I now think we are in the final stretch in the next 12 months.I am looking forward to the summer & that C-Diff deal.

7 New conferences listed by Summit today looks exciting: http://www.summitplc.com/media/events/

Hi Admington I think it is a matter of no news is good at the moment & I do not expect the next sum from Sarepta will be soon either hopefully Qtr 2 2017.There is not even a conference to wet our appetites.Regards.

Per football from the other board; youtube video 2/5/17 Publishing of Phase II ridinilazole study in Lancet 'a significant achievement' for Summit http://www.youtube.com/watch?v=s-sDvR8QH28

Sarepta Therapeutics May Attract Activist Attention https://www.thestreet.com/story/14112000/1/sarepta-therapeutics-may-attract-activist-attention.html Makes for interesting reading I wonder where Summit would fit in this?